Empirical evidence of neuroprotection by dual cholinesterase inhibition in Alzheimer's disease

A Venneri, WJ McGeown, MF Shanks

Research output: Contribution to journalArticle

52 Citations (Scopus)

Abstract

Brain grey matter density changes were quantified using voxel based morphometry in 26 patients with minimal to mild Alzheimer's disease (AD) treated with three cholinesterase inhibitors over 20 weeks. Patients whose drug treatment also inhibited butyrylcholinesterase did not show the widespread cortical atrophic changes in parietotemporal regions invariably reported in untreated AD patients, and which were detectable in the subgroups treated with selective acetylcholinesterase inhibition. This finding is the first empirical evidence that dual cholinesterase inhibition may have neuroprotective potential in AD. (C) 2005 Lippincott Williams Wilkins.

LanguageEnglish
Pages107-110
Number of pages4
JournalNeuroReport
Volume16
Issue number2
Publication statusPublished - 8 Feb 2005

Fingerprint

Cholinesterases
Alzheimer Disease
Butyrylcholinesterase
Cholinesterase Inhibitors
Acetylcholinesterase
Brain
Pharmaceutical Preparations
Inhibition (Psychology)
Neuroprotection
Therapeutics

Keywords

  • treatment
  • Alzheimer's disease
  • dementia
  • cholinesterase inhibitors
  • disease progression
  • donepezil
  • neuroimaging
  • grey matter
  • rivastigmine
  • galantamine
  • MRI

Cite this

@article{fc87cf57a82949629217fa44c020fd04,
title = "Empirical evidence of neuroprotection by dual cholinesterase inhibition in Alzheimer's disease",
abstract = "Brain grey matter density changes were quantified using voxel based morphometry in 26 patients with minimal to mild Alzheimer's disease (AD) treated with three cholinesterase inhibitors over 20 weeks. Patients whose drug treatment also inhibited butyrylcholinesterase did not show the widespread cortical atrophic changes in parietotemporal regions invariably reported in untreated AD patients, and which were detectable in the subgroups treated with selective acetylcholinesterase inhibition. This finding is the first empirical evidence that dual cholinesterase inhibition may have neuroprotective potential in AD. (C) 2005 Lippincott Williams Wilkins.",
keywords = "treatment, Alzheimer's disease, dementia, cholinesterase inhibitors, disease progression, donepezil, neuroimaging, grey matter, rivastigmine, galantamine, MRI",
author = "A Venneri and WJ McGeown and MF Shanks",
year = "2005",
month = "2",
day = "8",
language = "English",
volume = "16",
pages = "107--110",
journal = "NeuroReport",
issn = "0959-4965",
number = "2",

}

Empirical evidence of neuroprotection by dual cholinesterase inhibition in Alzheimer's disease. / Venneri, A; McGeown, WJ; Shanks, MF.

In: NeuroReport, Vol. 16, No. 2, 08.02.2005, p. 107-110.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Empirical evidence of neuroprotection by dual cholinesterase inhibition in Alzheimer's disease

AU - Venneri, A

AU - McGeown, WJ

AU - Shanks, MF

PY - 2005/2/8

Y1 - 2005/2/8

N2 - Brain grey matter density changes were quantified using voxel based morphometry in 26 patients with minimal to mild Alzheimer's disease (AD) treated with three cholinesterase inhibitors over 20 weeks. Patients whose drug treatment also inhibited butyrylcholinesterase did not show the widespread cortical atrophic changes in parietotemporal regions invariably reported in untreated AD patients, and which were detectable in the subgroups treated with selective acetylcholinesterase inhibition. This finding is the first empirical evidence that dual cholinesterase inhibition may have neuroprotective potential in AD. (C) 2005 Lippincott Williams Wilkins.

AB - Brain grey matter density changes were quantified using voxel based morphometry in 26 patients with minimal to mild Alzheimer's disease (AD) treated with three cholinesterase inhibitors over 20 weeks. Patients whose drug treatment also inhibited butyrylcholinesterase did not show the widespread cortical atrophic changes in parietotemporal regions invariably reported in untreated AD patients, and which were detectable in the subgroups treated with selective acetylcholinesterase inhibition. This finding is the first empirical evidence that dual cholinesterase inhibition may have neuroprotective potential in AD. (C) 2005 Lippincott Williams Wilkins.

KW - treatment

KW - Alzheimer's disease

KW - dementia

KW - cholinesterase inhibitors

KW - disease progression

KW - donepezil

KW - neuroimaging

KW - grey matter

KW - rivastigmine

KW - galantamine

KW - MRI

UR - http://journals.lww.com/neuroreport/Abstract/2005/02080/Empirical_evidence_of_neuroprotection_by_dual.6.aspx

M3 - Article

VL - 16

SP - 107

EP - 110

JO - NeuroReport

T2 - NeuroReport

JF - NeuroReport

SN - 0959-4965

IS - 2

ER -